+357 96 030922
info@marketpublishers.com

Global TROP2 Antibody-Drug Conjugate Market 2026 by Company, Regions, Type and Application, Forecast to 2032

https://marketpublishers.com/r/G9F93D80C162EN.html
Date: September 2026
Pages: 73
Price: US$ 3,480.00 (Single User License)
ID: G9F93D80C162EN

Abstracts

According to our (Global Info Research) latest study, the global TROP2 Antibody-Drug Conjugate market size was valued at US$ 1774 million in 2025 and is forecast to a readjusted size of US$ 4556 million by 2032 with a CAGR of 13.3% during review period.

TROP2 Antibody-Drug Conjugate refers to targeted anticancer therapeutics that combine a monoclonal antibody directed against trophoblast cell-surface antigen 2 (TROP2) with a cytotoxic payload through a designed chemical linker. After binding to TROP2-expressing tumor cells, the ADC is internalized or releases active payload within the tumor microenvironment, enabling targeted delivery of potent cytotoxic agents while seeking to improve the therapeutic index relative to conventional systemic chemotherapy. The current commercial product scope is centered on sacituzumab govitecan, datopotamab deruxtecan and sacituzumab tirumotecan, representing differentiated architectures based on SN-38, DXd and belotecan-derived topoisomerase I inhibitor payloads, respectively. Linker design ranges from hydrolyzable systems to tetrapeptide-based cleavable and other proprietary linker technologies, creating differences in payload release, bystander activity, stability and safety profiles. Commercial use currently spans TROP2 ADC monotherapy and combination regimens, with principal applications in triple-negative breast cancer, HR-positive/HER2-negative breast cancer and EGFR-mutated non-small cell lung cancer.

Key Findings

Commercial TROP2 ADC market centers on three approved core molecules

+357 96 030922
info@marketpublishers.com

Breast cancer remains the principal commercial application for TROP2 ADCs

EGFR-mutated NSCLC is an established commercial expansion pathway

Topoisomerase I inhibitor payloads dominate current commercial product architectures

Earlier-line and combination regimens are reshaping addressable treatment settings

Market Trends

The TROP2 Antibody-Drug Conjugate market is moving from a predominantly later-line rescue-treatment model toward broader positioning across treatment sequences. Recent regulatory progress illustrates this transition: datopotamab deruxtecan obtained U.S. approval for HR-positive/HER2-negative breast cancer in January 2025, EGFR-mutated NSCLC in June 2025 and selected unresectable or metastatic TNBC in May 2026, while Trodelvy expanded into first-line metastatic TNBC in the United States in June 2026. In China, sacituzumab tirumotecan has continued to broaden its approved breast cancer and EGFR-mutated NSCLC indications. These developments indicate that market competition is increasingly shifting from simply establishing TROP2 as a valid target toward optimizing ADC architecture, treatment-line positioning and combination strategies. Product development is also placing greater emphasis on linker stability, payload characteristics, bystander effect and tolerability, as these parameters influence whether TROP2 ADCs can penetrate earlier treatment lines and larger patient populations.

Market Dynamics

Drivers

The primary market driver is the continuing unmet treatment need in advanced breast cancer and EGFR-mutated NSCLC after resistance or progression following established systemic therapies. TROP2 provides a clinically validated cell-surface target for delivering highly potent topoisomerase I inhibitors, allowing ADCs to combine antibody-guided targeting with cytotoxic activity. Expansion of regulatory labels is progressively

+357 96 030922
info@marketpublishers.com

increasing the eligible patient population, particularly as products move from heavily pretreated patients toward earlier treatment lines. The commercial validation of multiple differentiated TROP2 ADC platforms also strengthens physician familiarity with the modality and supports investment in additional indication development, combination regimens and lifecycle expansion.

Restraints

Market expansion is constrained by the safety-management requirements inherent to highly potent ADCs and by the complexity of manufacturing antibody, linker and cytotoxic payload components as one consistently controlled pharmaceutical product. Different TROP2 ADCs exhibit distinct toxicity profiles: Trodelvy labeling highlights clinically important neutropenia and diarrhea, while datopotamab deruxtecan requires management of risks including interstitial lung disease or pneumonitis, ocular adverse reactions and stomatitis. These adverse-event profiles can influence patient selection, monitoring intensity, dose management and treatment sequencing. At the manufacturing level, stringent requirements for conjugation consistency, payload containment, analytical characterization and batch release also create higher technical barriers than conventional monoclonal antibody production.

Opportunities

The most attractive opportunities lie in increasing penetration within the three established application areas rather than relying solely on expansion into new tumor types. In TNBC and HR-positive/HER2-negative breast cancer, movement into earlier treatment lines could materially enlarge the addressable population, while combination regimens may extend the role of TROP2 ADCs beyond standalone therapy. In EGFR-mutated NSCLC, the emergence of approved TROP2 ADC options after targeted therapy and chemotherapy establishes a new commercial treatment category and creates opportunities for improved sequencing with existing targeted regimens. Continued optimization of linker-payload chemistry may further improve therapeutic index and help differentiate products within increasingly competitive breast and lung cancer treatment pathways.

Challenges

The principal long-term challenge is demonstrating sufficient clinical differentiation as

+357 96 030922
info@marketpublishers.com

several TROP2 ADCs compete for overlapping patient populations. Market success will increasingly depend on comparative efficacy, durability of response, safety, treatment-line positioning and compatibility with combination therapy rather than target novelty alone. Another challenge is treatment sequencing, particularly in breast cancer where oncologists have access to multiple targeted therapies and other ADC modalities. Biomarker strategy also remains important: TROP2 is broadly expressed, but optimal patient selection may depend on tumor biology, previous therapy and the specific characteristics of each ADC platform. Regulatory requirements for confirmatory studies, particularly where accelerated approval pathways are used, add further commercialization uncertainty.

Industry Chain Analysis

The TROP2 Antibody-Drug Conjugate industry chain integrates biologics manufacturing with highly potent small-molecule chemistry. Upstream inputs include anti-TROP2 monoclonal antibodies or antibody manufacturing materials, cytotoxic payload intermediates, linker compounds, conjugation reagents, cell-culture media, chromatography materials and specialized analytical technologies. The midstream stage involves antibody production, payload and linker synthesis, linker-payload preparation, controlled conjugation, purification, characterization, formulation and sterile fill-finish. Manufacturing quality depends not only on antibody purity but also on drug-to-antibody ratio, conjugation distribution, free payload levels, aggregation, linker stability and other critical quality attributes.

Value creation is therefore concentrated in integrated platform capability rather than in any single raw material. Companies able to coordinate antibody engineering, medicinal chemistry, conjugation technology, process development, analytical testing and commercial-scale manufacturing are better positioned to control product consistency and support indication expansion. Downstream commercialization is concentrated in oncology hospitals and specialist treatment networks, where medical affairs, reimbursement access, adverse-event management and physician education materially influence product adoption. The technical complexity of ADC production creates relatively high development and manufacturing barriers, while commercial value is increasingly determined by clinical differentiation and the breadth of approved treatment settings.

Segment Insights

+357 96 030922
info@marketpublishers.com

By Type, the current commercial market is structured around sacituzumab govitecan, datopotamab deruxtecan and sacituzumab tirumotecan, each representing a distinct TROP2 ADC platform. By Class, the products are differentiated primarily by topoisomerase I inhibitor payload technology: SN-38, DXd and a belotecan-derived payload. Although all three architectures use the same broad cytotoxic mechanism class, differences in payload potency, membrane permeability, drug-to-antibody ratio and release behavior create materially different pharmacological profiles. Trodelvy uses a hydrolyzable linker linked to SN-38, datopotamab deruxtecan uses a tetrapeptide-based cleavable linker with a DXd payload, while sacituzumab tirumotecan uses a proprietary linker with a belotecan-derived topoisomerase I inhibitor payload.

By Sort, monotherapy currently provides the commercial foundation of the category, while combination therapy represents an increasingly important expansion direction. The distinction is strategically significant because a successful combination regimen can move a TROP2 ADC into earlier treatment lines and integrate it into established immunotherapy or targeted-treatment pathways. As the category matures, competitive differentiation is expected to shift increasingly toward the balance between efficacy, tolerability and ease of combination rather than target selection itself.

Downstream Market Opportunities

Downstream demand is concentrated in advanced and metastatic breast cancer and EGFR-mutated NSCLC treatment settings. TNBC offers substantial opportunity as TROP2 ADCs move from later-line treatment toward first-line use, while HR-positive/HER2-negative breast cancer provides a large post-endocrine-therapy population requiring additional systemic treatment options. In EGFR-mutated NSCLC, TROP2 ADCs address patients who progress after EGFR-targeted therapy and chemotherapy, establishing a clinically distinct downstream market. Future commercial upside within these applications will depend on earlier-line penetration, combination strategies, treatment duration, reimbursement accessibility and successful integration into oncology treatment algorithms. The most commercially attractive opportunity is therefore not simply adding more tumor types, but increasing the proportion of eligible patients within already validated breast and lung cancer pathways.

Regional Insights

North America and China are currently important commercialization and regulatory-

+357 96 030922
info@marketpublishers.com

development markets for TROP2 ADCs. The United States has experienced rapid label expansion across the established application spectrum: datopotamab deruxtecan has gained approvals in HR-positive/HER2-negative breast cancer, EGFR-mutated NSCLC and selected TNBC populations, while Trodelvy expanded into first-line metastatic TNBC in June 2026. This creates a relatively mature competitive environment in which treatment sequencing, clinical differentiation and combination use are becoming increasingly important.

China has developed a differentiated market structure around sacituzumab tirumotecan, which has progressively expanded from TNBC into EGFR-mutated NSCLC and HR-positive/HER2-negative breast cancer. By February 2026, the product had received approval for a fourth indication in China, demonstrating rapid lifecycle expansion within the defined market applications. Europe and Japan remain relevant commercial markets, but regional adoption is influenced by country-specific regulatory timing, reimbursement assessment and oncology-treatment pathways. These differences mean that global competition will not necessarily translate into identical product sequencing or commercial positioning across regions.

Competitive Landscape Analysis

The competitive landscape is defined by a small number of commercial TROP2 ADC platforms with increasingly overlapping indications. Gilead Sciences has established Trodelvy across TNBC and HR-positive/HER2-negative breast cancer and has expanded its U.S. positioning into first-line metastatic TNBC. Daiichi Sankyo and AstraZeneca jointly develop datopotamab deruxtecan, whose commercial footprint now spans HR-positive/HER2-negative breast cancer, EGFR-mutated NSCLC and selected TNBC populations in the United States. Kelun-Biotech has built sacituzumab tirumotecan into a commercial TROP2 ADC platform in China across the same major breast and lung cancer application areas. Competition is therefore evolving beyond first-mover advantage. Product architecture, efficacy-to-toxicity balance, treatment-line breadth, combination strategy, manufacturing capability, regulatory execution and market access are becoming more important determinants of competitive position. The market remains sufficiently concentrated for individual label expansions to alter competitive dynamics materially, particularly when they move a product into an earlier treatment line or a major additional application.

Report Scope

+357 96 030922
info@marketpublishers.com

This report is a detailed and comprehensive analysis for global TROP2 Antibody-Drug Conjugate market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global TROP2 Antibody-Drug Conjugate market size and forecasts, in consumption value ($ Million), 2021-2032

Global TROP2 Antibody-Drug Conjugate market size and forecasts by region and country, in consumption value ($ Million), 2021-2032

Global TROP2 Antibody-Drug Conjugate market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032

Global TROP2 Antibody-Drug Conjugate market shares of main players, in revenue ($ Million), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for TROP2 Antibody-Drug Conjugate

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global TROP2 Antibody-Drug Conjugate market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Daiichi Sankyo, AstraZeneca, Sichuan Kelun-

+357 96 030922
info@marketpublishers.com

Biotech Biopharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

TROP2 Antibody-Drug Conjugate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Market segment by Type

Intramuscular Injection

Intravenous Injection

Market segment by Drugs Type

Sacituzumab Govitecan

Datopotamab Deruxtecan

Sacituzumab Tirumotecan

Market segment by Treatment Mode

ROP2 ADC Monotherapy

TROP2 ADC Combination Therapy

Market segment by Application

+357 96 030922
info@marketpublishers.com

Triple-Negative Breast Cancer

HR-Positive/HER2-Negative Breast Cancer

EGFR-Mutated Non-Small Cell Lung Cancer

Market segment by players, this report covers

Gilead Sciences

Daiichi Sankyo

AstraZeneca

Sichuan Kelun-Biotech Biopharmaceutical

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Chapter Outline

Chapter 1, to describe TROP2 Antibody-Drug Conjugate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of TROP2 Antibody-Drug Conjugate, with revenue, gross margin, and global market share of TROP2 Antibody-Drug Conjugate from 2021

+357 96 030922
info@marketpublishers.com

to 2026.
Chapter 3, the TROP2 Antibody-Drug Conjugate competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and TROP2 Antibody-Drug Conjugate market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of TROP2 Antibody-Drug Conjugate.
Chapter 13, to describe TROP2 Antibody-Drug Conjugate research findings and conclusion.

+357 96 030922
info@marketpublishers.com

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of TROP2 Antibody-Drug Conjugate by Type
  1.3.1 Overview: Global TROP2 Antibody-Drug Conjugate Market Size by Type: 2021 Versus 2025 Versus 2032
  1.3.2 Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Type in 2025
  1.3.3 Intramuscular Injection
  1.3.4 Intravenous Injection
1.4 Classification of TROP2 Antibody-Drug Conjugate by Drugs Type
  1.4.1 Overview: Global TROP2 Antibody-Drug Conjugate Market Size by Drugs Type: 2021 Versus 2025 Versus 2032
  1.4.2 Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Drugs Type in 2025
  1.4.3 Sacituzumab Govitecan
  1.4.4 Datopotamab Deruxtecan
  1.4.5 Sacituzumab Tirumotecan
1.5 Classification of TROP2 Antibody-Drug Conjugate by Treatment Mode
  1.5.1 Overview: Global TROP2 Antibody-Drug Conjugate Market Size by Treatment Mode: 2021 Versus 2025 Versus 2032
  1.5.2 Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Treatment Mode in 2025
  1.5.3 ROP2 ADC Monotherapy
  1.5.4 TROP2 ADC Combination Therapy
1.6 Global TROP2 Antibody-Drug Conjugate Market by Application
  1.6.1 Overview: Global TROP2 Antibody-Drug Conjugate Market Size by Application: 2021 Versus 2025 Versus 2032
  1.6.2 Triple-Negative Breast Cancer
  1.6.3 HR-Positive/HER2-Negative Breast Cancer
  1.6.4 EGFR-Mutated Non-Small Cell Lung Cancer
1.7 Global TROP2 Antibody-Drug Conjugate Market Size & Forecast
1.8 Global TROP2 Antibody-Drug Conjugate Market Size and Forecast by Region
  1.8.1 Global TROP2 Antibody-Drug Conjugate Market Size by Region: 2021 VS 2025 VS 2032
  1.8.2 Global TROP2 Antibody-Drug Conjugate Market Size by Region, (2021-2032)

+357 96 030922
info@marketpublishers.com

1.8.3 North America TROP2 Antibody-Drug Conjugate Market Size and Prospect (2021-2032)
1.8.4 Europe TROP2 Antibody-Drug Conjugate Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific TROP2 Antibody-Drug Conjugate Market Size and Prospect (2021-2032)
1.8.6 South America TROP2 Antibody-Drug Conjugate Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa TROP2 Antibody-Drug Conjugate Market Size and Prospect (2021-2032)

2 COMPANY PROFILES

2.1 Gilead Sciences
2.1.1 Gilead Sciences Details
2.1.2 Gilead Sciences Major Business
2.1.3 Gilead Sciences TROP2 Antibody-Drug Conjugate Product and Solutions
2.1.4 Gilead Sciences TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Gilead Sciences Recent Developments and Future Plans
2.2 Daiichi Sankyo
2.2.1 Daiichi Sankyo Details
2.2.2 Daiichi Sankyo Major Business
2.2.3 Daiichi Sankyo TROP2 Antibody-Drug Conjugate Product and Solutions
2.2.4 Daiichi Sankyo TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Daiichi Sankyo Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca TROP2 Antibody-Drug Conjugate Product and Solutions
2.3.4 AstraZeneca TROP2 Antibody-Drug Conjugate Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Sichuan Kelun-Biotech Biopharmaceutical
2.4.1 Sichuan Kelun-Biotech Biopharmaceutical Details
2.4.2 Sichuan Kelun-Biotech Biopharmaceutical Major Business
2.4.3 Sichuan Kelun-Biotech Biopharmaceutical TROP2 Antibody-Drug Conjugate Product and Solutions
2.4.4 Sichuan Kelun-Biotech Biopharmaceutical TROP2 Antibody-Drug Conjugate

+357 96 030922
info@marketpublishers.com

Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Sichuan Kelun-Biotech Biopharmaceutical Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global TROP2 Antibody-Drug Conjugate Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of TROP2 Antibody-Drug Conjugate by Company Revenue
3.2.2 Top 3 TROP2 Antibody-Drug Conjugate Players Market Share in 2025
3.2.3 Top 6 TROP2 Antibody-Drug Conjugate Players Market Share in 2025
3.3 TROP2 Antibody-Drug Conjugate Market: Overall Company Footprint Analysis
3.3.1 TROP2 Antibody-Drug Conjugate Market: Region Footprint
3.3.2 TROP2 Antibody-Drug Conjugate Market: Company Product Type Footprint
3.3.3 TROP2 Antibody-Drug Conjugate Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global TROP2 Antibody-Drug Conjugate Consumption Value and Market Share by Type (2021-2026)
4.2 Global TROP2 Antibody-Drug Conjugate Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Application (2021-2026)
5.2 Global TROP2 Antibody-Drug Conjugate Market Forecast by Application (2027-2032)

6 NORTH AMERICA

6.1 North America TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2032)
6.2 North America TROP2 Antibody-Drug Conjugate Market Size by Application (2021-2032)

+357 96 030922
info@marketpublishers.com

6.3 North America TROP2 Antibody-Drug Conjugate Market Size by Country
6.3.1 North America TROP2 Antibody-Drug Conjugate Consumption Value by Country (2021-2032)
6.3.2 United States TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
6.3.3 Canada TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
6.3.4 Mexico TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)

7 EUROPE

7.1 Europe TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2032)
7.2 Europe TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2032)
7.3 Europe TROP2 Antibody-Drug Conjugate Market Size by Country
7.3.1 Europe TROP2 Antibody-Drug Conjugate Consumption Value by Country (2021-2032)
7.3.2 Germany TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
7.3.3 France TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
7.3.4 United Kingdom TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
7.3.5 Russia TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
7.3.6 Italy TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)

8 ASIA-PACIFIC

8.1 Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2032)
8.2 Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2032)
8.3 Asia-Pacific TROP2 Antibody-Drug Conjugate Market Size by Region
8.3.1 Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Region (2021-2032)
8.3.2 China TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
8.3.3 Japan TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
8.3.4 South Korea TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
8.3.5 India TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)

+357 96 030922
info@marketpublishers.com

8.3.6 Southeast Asia TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
8.3.7 Australia TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)

9 SOUTH AMERICA

9.1 South America TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2032)
9.2 South America TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2032)
9.3 South America TROP2 Antibody-Drug Conjugate Market Size by Country
9.3.1 South America TROP2 Antibody-Drug Conjugate Consumption Value by Country (2021-2032)
9.3.2 Brazil TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
9.3.3 Argentina TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2032)
10.2 Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2032)
10.3 Middle East & Africa TROP2 Antibody-Drug Conjugate Market Size by Country
10.3.1 Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by Country (2021-2032)
10.3.2 Turkey TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)
10.3.4 UAE TROP2 Antibody-Drug Conjugate Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 TROP2 Antibody-Drug Conjugate Market Drivers
11.2 TROP2 Antibody-Drug Conjugate Market Restraints
11.3 TROP2 Antibody-Drug Conjugate Trends Analysis
11.4 Porters Five Forces Analysis

+357 96 030922
info@marketpublishers.com

11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 TROP2 Antibody-Drug Conjugate Industry Chain
12.2 TROP2 Antibody-Drug Conjugate Upstream Analysis
12.3 TROP2 Antibody-Drug Conjugate Midstream Analysis
12.4 TROP2 Antibody-Drug Conjugate Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. Global TROP2 Antibody-Drug Conjugate Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global TROP2 Antibody-Drug Conjugate Consumption Value by Drugs Type, (USD Million), 2021 & 2025 & 2032
Table 3. Global TROP2 Antibody-Drug Conjugate Consumption Value by Treatment Mode, (USD Million), 2021 & 2025 & 2032
Table 4. Global TROP2 Antibody-Drug Conjugate Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global TROP2 Antibody-Drug Conjugate Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global TROP2 Antibody-Drug Conjugate Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 8. Gilead Sciences Major Business
Table 9. Gilead Sciences TROP2 Antibody-Drug Conjugate Product and Solutions
Table 10. Gilead Sciences TROP2 Antibody-Drug Conjugate Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Gilead Sciences Recent Developments and Future Plans
Table 12. Daiichi Sankyo Company Information, Head Office, and Major Competitors
Table 13. Daiichi Sankyo Major Business
Table 14. Daiichi Sankyo TROP2 Antibody-Drug Conjugate Product and Solutions
Table 15. Daiichi Sankyo TROP2 Antibody-Drug Conjugate Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Daiichi Sankyo Recent Developments and Future Plans
Table 17. AstraZeneca Company Information, Head Office, and Major Competitors
Table 18. AstraZeneca Major Business
Table 19. AstraZeneca TROP2 Antibody-Drug Conjugate Product and Solutions
Table 20. AstraZeneca TROP2 Antibody-Drug Conjugate Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Sichuan Kelun-Biotech Biopharmaceutical Company Information, Head Office, and Major Competitors
Table 22. Sichuan Kelun-Biotech Biopharmaceutical Major Business
Table 23. Sichuan Kelun-Biotech Biopharmaceutical TROP2 Antibody-Drug Conjugate Product and Solutions
Table 24. Sichuan Kelun-Biotech Biopharmaceutical TROP2 Antibody-Drug Conjugate

+357 96 030922
info@marketpublishers.com

Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Sichuan Kelun-Biotech Biopharmaceutical Recent Developments and Future Plans
Table 26. Global TROP2 Antibody-Drug Conjugate Revenue (USD Million) by Players (2021-2026)
Table 27. Global TROP2 Antibody-Drug Conjugate Revenue Share by Players (2021-2026)
Table 28. Breakdown of TROP2 Antibody-Drug Conjugate by Company Type (Tier 1, Tier 2, and Tier 3)
Table 29. Market Position of Players in TROP2 Antibody-Drug Conjugate, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 30. Head Office of Key TROP2 Antibody-Drug Conjugate Players
Table 31. TROP2 Antibody-Drug Conjugate Market: Company Product Type Footprint
Table 32. TROP2 Antibody-Drug Conjugate Market: Company Product Application Footprint
Table 33. TROP2 Antibody-Drug Conjugate New Market Entrants and Barriers to Market Entry
Table 34. TROP2 Antibody-Drug Conjugate Mergers, Acquisition, Agreements, and Collaborations
Table 35. Global TROP2 Antibody-Drug Conjugate Consumption Value (USD Million) by Type (2021-2026)
Table 36. Global TROP2 Antibody-Drug Conjugate Consumption Value Share by Type (2021-2026)
Table 37. Global TROP2 Antibody-Drug Conjugate Consumption Value Forecast by Type (2027-2032)
Table 38. Global TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2026)
Table 39. Global TROP2 Antibody-Drug Conjugate Consumption Value Forecast by Application (2027-2032)
Table 40. North America TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2026) & (USD Million)
Table 41. North America TROP2 Antibody-Drug Conjugate Consumption Value by Type (2027-2032) & (USD Million)
Table 42. North America TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2026) & (USD Million)
Table 43. North America TROP2 Antibody-Drug Conjugate Consumption Value by Application (2027-2032) & (USD Million)
Table 44. North America TROP2 Antibody-Drug Conjugate Consumption Value by Country (2021-2026) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 45. North America TROP2 Antibody-Drug Conjugate Consumption Value by Country (2027-2032) & (USD Million)
Table 46. Europe TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2026) & (USD Million)
Table 47. Europe TROP2 Antibody-Drug Conjugate Consumption Value by Type (2027-2032) & (USD Million)
Table 48. Europe TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2026) & (USD Million)
Table 49. Europe TROP2 Antibody-Drug Conjugate Consumption Value by Application (2027-2032) & (USD Million)
Table 50. Europe TROP2 Antibody-Drug Conjugate Consumption Value by Country (2021-2026) & (USD Million)
Table 51. Europe TROP2 Antibody-Drug Conjugate Consumption Value by Country (2027-2032) & (USD Million)
Table 52. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2026) & (USD Million)
Table 53. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Type (2027-2032) & (USD Million)
Table 54. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2026) & (USD Million)
Table 55. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Application (2027-2032) & (USD Million)
Table 56. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Region (2021-2026) & (USD Million)
Table 57. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value by Region (2027-2032) & (USD Million)
Table 58. South America TROP2 Antibody-Drug Conjugate Consumption Value by Type (2021-2026) & (USD Million)
Table 59. South America TROP2 Antibody-Drug Conjugate Consumption Value by Type (2027-2032) & (USD Million)
Table 60. South America TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2026) & (USD Million)
Table 61. South America TROP2 Antibody-Drug Conjugate Consumption Value by Application (2027-2032) & (USD Million)
Table 62. South America TROP2 Antibody-Drug Conjugate Consumption Value by Country (2021-2026) & (USD Million)
Table 63. South America TROP2 Antibody-Drug Conjugate Consumption Value by Country (2027-2032) & (USD Million)
Table 64. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by

+357 96 030922
info@marketpublishers.com

Type (2021-2026) & (USD Million)
Table 65. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by Type (2027-2032) & (USD Million)
Table 66. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by Application (2021-2026) & (USD Million)
Table 67. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by Application (2027-2032) & (USD Million)
Table 68. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by Country (2021-2026) & (USD Million)
Table 69. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value by Country (2027-2032) & (USD Million)
Table 70. Global Key Players of TROP2 Antibody-Drug Conjugate Upstream (Raw Materials)
Table 71. Global TROP2 Antibody-Drug Conjugate Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. TROP2 Antibody-Drug Conjugate Picture
Figure 2. Global TROP2 Antibody-Drug Conjugate Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Type in 2025
Figure 4. Intramuscular Injection
Figure 5. Intravenous Injection
Figure 6. Global TROP2 Antibody-Drug Conjugate Consumption Value by Drugs Type, (USD Million), 2021 & 2025 & 2032
Figure 7. Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Drugs Type in 2025
Figure 8. Sacituzumab Govitecan
Figure 9. Datopotamab Deruxtecan
Figure 10. Sacituzumab Tirumotecan
Figure 11. Global TROP2 Antibody-Drug Conjugate Consumption Value by Treatment Mode, (USD Million), 2021 & 2025 & 2032
Figure 12. Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Treatment Mode in 2025
Figure 13. ROP2 ADC Monotherapy
Figure 14. TROP2 ADC Combination Therapy
Figure 15. Global TROP2 Antibody-Drug Conjugate Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 16. TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Application in 2025
Figure 17. Triple-Negative Breast Cancer Picture
Figure 18. HR-Positive/HER2-Negative Breast Cancer Picture
Figure 19. EGFR-Mutated Non-Small Cell Lung Cancer Picture
Figure 20. Global TROP2 Antibody-Drug Conjugate Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 21. Global TROP2 Antibody-Drug Conjugate Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 22. Global Market TROP2 Antibody-Drug Conjugate Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 23. Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Region (2021-2032)

+357 96 030922
info@marketpublishers.com

Figure 24. Global TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Region in 2025
Figure 25. North America TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 26. Europe TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 27. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 28. South America TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 29. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 30. Company Three Recent Developments and Future Plans
Figure 31. Global TROP2 Antibody-Drug Conjugate Revenue Share by Players in 2025
Figure 32. TROP2 Antibody-Drug Conjugate Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 33. Market Share of TROP2 Antibody-Drug Conjugate by Player Revenue in 2025
Figure 34. Top 3 TROP2 Antibody-Drug Conjugate Players Market Share in 2025
Figure 35. Top 6 TROP2 Antibody-Drug Conjugate Players Market Share in 2025
Figure 36. Global TROP2 Antibody-Drug Conjugate Consumption Value Share by Type (2021-2026)
Figure 37. Global TROP2 Antibody-Drug Conjugate Market Share Forecast by Type (2027-2032)
Figure 38. Global TROP2 Antibody-Drug Conjugate Consumption Value Share by Application (2021-2026)
Figure 39. Global TROP2 Antibody-Drug Conjugate Market Share Forecast by Application (2027-2032)
Figure 40. North America TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Type (2021-2032)
Figure 41. North America TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Application (2021-2032)
Figure 42. North America TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Country (2021-2032)
Figure 43. United States TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 44. Canada TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 45. Mexico TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) &

+357 96 030922
info@marketpublishers.com

(USD Million)
Figure 46. Europe TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Type (2021-2032)
Figure 47. Europe TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Application (2021-2032)
Figure 48. Europe TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Country (2021-2032)
Figure 49. Germany TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 50. France TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 51. United Kingdom TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 52. Russia TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 53. Italy TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 54. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Type (2021-2032)
Figure 55. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Application (2021-2032)
Figure 56. Asia-Pacific TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Region (2021-2032)
Figure 57. China TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 58. Japan TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 59. South Korea TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 60. India TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 61. Southeast Asia TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 62. Australia TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 63. South America TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Type (2021-2032)
Figure 64. South America TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Application (2021-2032)

+357 96 030922
info@marketpublishers.com

Figure 65. South America TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Country (2021-2032)
Figure 66. Brazil TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 67. Argentina TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 68. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Type (2021-2032)
Figure 69. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Application (2021-2032)
Figure 70. Middle East & Africa TROP2 Antibody-Drug Conjugate Consumption Value Market Share by Country (2021-2032)
Figure 71. Turkey TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 72. Saudi Arabia TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 73. UAE TROP2 Antibody-Drug Conjugate Consumption Value (2021-2032) & (USD Million)
Figure 74. TROP2 Antibody-Drug Conjugate Market Drivers
Figure 75. TROP2 Antibody-Drug Conjugate Market Restraints
Figure 76. TROP2 Antibody-Drug Conjugate Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. TROP2 Antibody-Drug Conjugate Industrial Chain
Figure 79. Methodology
Figure 80. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global TROP2 Antibody-Drug Conjugate Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: https://marketpublishers.com/r/G9F93D80C162EN.html

Price: US$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G9F93D80C162EN.html